Not Yet Recruiting PHASE2 INTERVENTIONAL 3-arm NCT06890039

A-TANGO Phase 2 Study (A-TANGO)

Phase II, Double-blind, Randomized, Placebo-controlled, Multicentre Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of TAK-242 and (G-CSF) in Subjects With (sAH) and (ACLF)

Sponsor: Assistance Publique - Hôpitaux de Paris

Conditions Acute-On-Chronic Liver Failure Alcoholic Hepatitis Liver Cirrhosis, Alcoholic

Interventions G-CSF (Filgrastim) Placebo TAK-242

Updated 2 times since 2025 Last updated: Jul 23, 2025 Started: Sep 1, 2025 Primary completion: Feb 28, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06890039, this PHASE2 trial focuses on Acute-On-Chronic Liver Failure and Alcoholic Hepatitis and remains actively recruiting participants. Sponsored by Assistance Publique - Hôpitaux de Paris, it has been updated 2 times since 2025, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

2 versions recorded

Aug 2025 — Present [monthly]

Not Yet Recruiting PHASE2
Apr 2025 — Aug 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assistance Publique - Hôpitaux de Paris
CROWDHELIX LIMITED
Charite University, Berlin, Germany
Concentris research management gmbh
EUROPEAN LIVER PATIENTS' ASSOCIATION
European Association for the Study of the Liver
European Foundation for Study of Chronic Liver Failure
HEPYX LIMITED
INTERNATIONAL MARKET ACCESS CONSULTING GMBH
KlinEra Global Services
Leiden University Medical Center
University College, London
University of Leipzig
Yaqrit Ltd

Data source: Yaqrit Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.